Back to News
Market Impact: 0.1

ETF Fundamental Report for SPYV

SPYVNDAQ
Company FundamentalsAnalyst InsightsInvestor Sentiment & PositioningMarket Technicals & FlowsHealthcare & Biotech
ETF Fundamental Report for SPYV

Validea's fundamental report on the SPDR Portfolio S&P 500 Value ETF (SPYV) identifies it as a Large-Cap Low Volatility ETF, with its largest sector exposure in Financials and industry in Biotechnology & Drugs. The ETF exhibits a high factor score of 85 for Low Volatility and a moderate 61 for Value, alongside 55 for Quality and 35 for Momentum, suggesting a stronger emphasis on stability than pure value despite its name.

Analysis

A fundamental report by Validea on the SPDR Portfolio S&P 500 Value ETF (SPYV) reveals a factor profile that emphasizes stability over pure value. Despite its name, the ETF's most prominent characteristic is its high Low Volatility score of 85 out of 99, positioning it as a defensive large-cap vehicle. Its exposure to the Value factor is more moderate, with a score of 61, while its Quality score is 55. Notably, the fund has a very low Momentum score of 35, indicating it is not constructed to chase recent market winners. The portfolio's largest sector exposure is to Financials, and its largest single industry is Biotechnology & Drugs, a specific concentration that contrasts with the fund's overarching low-volatility theme.

AllMind AI Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request a Demo

Market Sentiment

Overall Sentiment

neutral

Sentiment Score

0.00

Ticker Sentiment

NDAQ0.00
SPYV0.00

Key Decisions for Investors

  • Investors should primarily consider SPYV for its high low-volatility characteristics (score of 85), making it suitable for defensive positioning rather than for a pure deep-value strategy.
  • Be aware that the ETF's low momentum score of 35 suggests it may underperform in strongly trending, momentum-driven market environments.
  • Evaluate the significant exposure to the Financials sector and the Biotechnology & Drugs industry to ensure it aligns with your portfolio's existing diversification and risk appetite.